Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Snap (SNAP) upgraded to Outperform from Market Perform at JMP Securities with analyst Ronald Josey saying he is "incrementally confident" in Snap's ability to grow its user base, increase engagement, and improve overall monetization as the service attracts more advertisers and share of advertising budgets. 2. Ciena (CIEN) upgraded to Overweight from Neutral at Piper Jaffray with analyst Troy Jensen saying Ciena reported another strong quarter with October beating sales consensus estimates. 3. Bristol-Myers (BMY) upgraded to Buy from Hold at Argus with analyst David Toung saying his view on the progress of the company advancing the pipeline of assets combined with Celgene has improved, particularly with two Celgene drugs - Reblozyl and Inrebic - receiving FDA approval since the merger. 4. Bluebird Bio (BLUE) upgraded to Outperform from Perform at Oppenheimer with analyst Mark Breidenbach saying that given registration-enabling data for ide-cel in hand and undeniably positive updates for lentiglobin/Zynteglo presented at the American Society of Hematology meeting, he anticipates less headwind for bluebird heading into 2020. 5. NuVasive (NUVA) upgraded to Outperform from Market Perform at SVB Leerink with analyst Richard Newitter saying he raised his 2020-2021 sales and earnings forecasts above consensus, due to more bullish top-line growth assumptions, specifically in U.S. Spinal Hardware. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.